StockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)

StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research report report published on Sunday morning. The firm issued a buy rating on the biopharmaceutical company’s stock. Acorda Therapeutics Price Performance Shares of NASDAQ ACOR opened at $16.31 on Friday. The firm has a market cap of $20.26 million, a […]

Leave a Reply

Your email address will not be published.

Previous post Brooklyn ImmunoTherapeutics (NYSE:BTX) Receives New Coverage from Analysts at StockNews.com
Next post Amazon to cut hundreds of staff at Prime Video and MGM